Polynucleotide compositions and methods for treatment of cancer
AssigneeAptah Bio, Inc.
InventorCaio BRUNO QUINTA DE SOUZA LEAL
Life of this patent
Estimating the term…
Abstract
This disclosure provides an engineered polynucleotide that interacts with a pre-mRNA and a spliceosome to regulate gene expression. The engineered polynucleotide may have stem-loop structure that recruits the spliceosome and targeting sequences that are complementary to a target sequence at an exon-intron splice junction and may include nucleotides with 2′ modifications and phosphorothioate linkages. The engineered polynucleotide can be administered to a subject to treat a cancer.
Claims33
-132. (canceled)
A method of treating cancer in a subject in need thereof, the method comprising administering to the subject a pharmaceutical composition comprising an engineered polynucleotide comprising:
- (i) one or more targeting moieties, wherein a targeting moiety of the one or more targeting moieties comprises a nucleic acid sequence complementary to a target sequence, or consensus sequence thereof, of a pre-messenger ribonucleic acid (pre-mRNA);
- and
- (ii) a recruiting moiety for recruitment of a spliceosomal moiety, wherein the recruiting moeity comprises a nucleic acid sequence comprising (i) one or more nucleotides complementary to a sequence of a portion of a spliceosomal moiety or (ii) one or more chemically modified nucleotides,
- wherein, when associated with said pre-mRNA and said engineered polynucleotide, said spliceosomal moiety alters said pre-mRNA in or in proximity to said target sequence.
Dependencies are inferred from the claim text.